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Autoinflammatory diseases are caused by inflammasome dysregulation leading to overproduction of proinflammatory cytokines
and a pathological delay in the inflammation switching off. The progress of cellular biology has partially clarified pathogenic
mechanisms behind monogenic autoinflammatory diseases, whereas little is known about the polygenic ones. Although the
genetic susceptibility of periodic fever, aphthous stomatitis, pharyngitis, and adenopathy (PFAPA) syndrome is still obscure, the
presence of overlapping symptoms with monogenic periodic fevers, the recurrence in family members, the important role played
by dysregulated interleukin- (IL-) 1𝛽 secretion during flares, the overexpression of inflammasome-associated genes during attacks,
and, last but not least, the therapeutic efficacy of IL-1𝛽 blockade strongly indicate a potential genetic involvement in its pathogenesis,
probably linkedwith environmental factors. PFAPA syndromehas a typical inception in the pediatric age, but a delayed onset during
adulthood has been described as well. Treatments required as well as effectiveness of tonsillectomy remain controversial, even if the
disease seems to have a self-limited course mostly in children.The purpose of this review is to provide an overview of this complex
polygenic/multifactorial autoinflammatory disorder in which the innate immune system undoubtedly plays a basic role.
1. Introduction
By definition autoinflammatory diseases (AIDs) are charac-
terized by recurrent episodes of inflammation in the absence
of autoreactive T-cells and autoantibodies [1]. From the
understanding that the so-called monogenic periodic fevers
are the prototype of pure AIDs, our knowledge has now
expanded to encompassmultifactorial and polygenic diseases
among AIDs [2, 3]. PFAPA syndrome, along with other
disorders, such as Behc¸et disease [4, 5], recurrent idiopathic
pericarditis [6–8], adult-onset Still’s disease, and systemic-
onset juvenile idiopathic arthritis [9, 10], belongs to the
group of acquired AIDs on a potential multifactorial or
polygenic basis. The acronym PFAPA, epitomizing the most
characteristic symptoms of the syndrome (periodic fever,
aphthous stomatitis, pharyngitis, and cervical adenitis), was
coined along with the diagnostic criteria in 1989, 2 years after
the first description of this condition made by Marshall in
1987 [11]. This clinical entity is characterized by the regular
occurrence of high fever (generally >39∘C) associated with at
least one of three cardinal clinical signs: aphthous stomatitis,
pharyngitis, and cervical adenitis. PFAPA syndrome has been
well-described in pediatric patients, since in most cases
it occurs in young children, arising before the age of 5,
and represents the most frequent cause of periodic fever of
unknown origin in childhood, at least of rheumatologic inter-
est. Nonetheless, there is now mounting evidence that chil-
dren older than 5 years may present with the typical picture
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of PFAPA syndrome, and recent literature has depicted about
40 cases of onset in adulthood [12–14].This evidence suggests
that the age criterion (i.e., age at onset less than 5 years)
should not be considered among PFAPA diagnostic criteria
and that rheumatologists should be aware of the clinical
characteristics of this syndrome in order to suspect and
recognize this disease in their adult patients too.
2. Pathogenesis
Theexact pathogenesis of the disease has yet to be recognized.
Given the dominating symptoms, the occurrence in the first
years of life (when upper respiratory tract infections are very
frequent), and the efficacy of tonsillectomy, an infectious eti-
ology of the syndrome was firstly proposed [11]. On the other
hand, the lack of seasonal clustering and the observation that
pharyngeal and tonsil samples were invariably negative for
pathogens have led to partially abandoning this theory [12].
More recent theories, evoked by the response to corticos-
teroids and clinical overlapping with AIDs, have suggested
an immunologic dysregulation [15, 16]. The involvement
of tonsils made some authors look for specific histologic
findings [17]. Petra et al. investigated paired tonsils and
peripheral blood samples from 10 children with PFAPA
syndrome, who successfully recovered after tonsillectomy.
Most of the observed changes in distribution of B and T
lymphocytes, together with an elevation in gene expression
of T-cell chemoattractants, were restricted to tonsils, sug-
gesting recruitment to this site from the peripheral blood,
via impaired chemokine expression [18]. These results were
in accordance with another study, which found more IgD-
armed basophils (which are thought to play a role in the
balance between immunity and inflammation) in the tonsils
of PFAPA patients, compared to controls [19]. Even though
preliminary, these data altogether point to the tonsils as
central in the PFAPA pathogenesis and might partly explain
the therapeutic success of tonsillectomy in these patients.
It has been recently observed that several cytokines are
elevated during febrile episodes of PFAPA syndrome, primar-
ily interferon-gamma, tumour necrosis factor, interleukin-
(IL-) 6, and IL-1𝛽.The latter seems to be significantly secreted
by dysregulated monocytes during febrile flares and acts as
stimulator of T-cell function [20]. The central role of IL-1 in
PFAPA patients has been demonstrated also by Stojanov et
al., who further underlined the similarities between PFAPA
syndrome and hereditary periodic fevers (HPF) [21]. The
high incidence of family members with a history relevant
to PFAPA syndrome suggested that the disease could be
genetically determined, but the exact gene is far from being
identified [22–24]. Hypomorphic mutations in genes related
toHPFhave been described in PFAPApatients. Although this
finding needs to be confirmed in larger studies, it may suggest
a general model for PFAPA syndrome in which a microbial
trigger might give rise to the activation of innate immune
system and recruitment of activated T-cells in a susceptible
host [25].
In conclusion, even though the exact pathogenic mecha-
nism underlying PFAPA still remains unknown, the clinical
overlapping with monogenic HPF, the high rate of posi-
tive familial history in patients, the clearly central role of
proinflammatory cytokines, mainly IL-1 among them, and
the variable association with some hypomorphic mutations
of genes involved in HPF all point in our opinion to the
idea that PFAPA syndrome should be considered a polygenic
autoinflammatory disease [26–28].
3. Epidemiology
Although PFAPA syndrome is the most frequent cause
of recurrent fevers in children, at least of rheumatologist
concern, few pieces of data about its incidence can be found
in themedical literature.The largest cohort of patients derives
from an international database reporting 301 patients [14].
In a retrospective study carried out by Barbi et al. in Friuli
Venezia Giulia (a northern region in Italy) and involving
20 pediatricians, 40 cases of PFAPA syndrome fulfilling the
diagnostic criteria were detected during a 5-year period
(1996–2001): the approximate incidence was 0.4 cases/1000
children/year, with 1 new diagnosed case of PFAPA per
pediatrician every 1-2 years [29]. In a recent paper published
by Førsvoll et al. the incidence of PFAPA syndrome in
Norway was calculated to be 2.3 per 10.000 children up to
5 years of age [30]. As far as our experience is concerned,
we diagnosed 268 children with PFAPA syndrome, observing
an ascending climax in the distribution of cases per year: 2/3
of patients were evaluated in the period 1999–2010 and 1/3
during the period 2010–12, testifying that pediatricians are
becoming more aware of this syndrome. Data on the PFAPA
incidence in adults are completely lacking.
Episodes of fever in PFAPA syndrome generally begin
between the ages of two and five years [1, 15, 31]: there is a
slight male predominance, but no predilection for particular
ethnic groups [14]. Once considered peculiar for children
younger than 5, PFAPA syndrome is now known to affect
older children and adults as well. Padeh et al. described a
group of 15 adults with PFAPA clinical features [12]. More
recently, we described 17 adults with similar features of
unexplained recurrent fever, satisfying PFAPA criteria [16]. In
adults fulfilling the criteria for PFAPA syndrome no gender
predominance can be detected (Table 1). Even if no genetic
abnormalities have been described, a positive familial history
is referred in up to 40% of patients with PFAPA syndrome
[14, 22–24].
4. Clinical Features
As the PFAPA acronym stands for, fever is the dominant
symptom in children and the clinical element that prompts
child’s parents to ask for medical advice. Body temperature
usually increases up to 40.5∘C, lasts for 3–5 days, and is
quite resistant to the normally used antipyretics, such as
acetaminophen or ibuprofen. The most frequent accompa-
nying sign is the presence of erythematous or exudative
pharyngitis (i.e., present in up to 90% of patients), cervical
lymphadenopathy, with swollen and tender lymph nodes
(in up to 75% of patients), and oral aphthosis (in up to
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Table 1: Comparison between adult PFAPA and pediatric PFAPA syndrome regarding the main demographic and clinical characteristics and
response to treatment.
Adult PFAPA syndrome Pediatric PFAPA syndrome
Number of patients 36 268
Gender 18 M/18 F 148 M/120 F
Mean age at diagnosis 30.3 ± 9.3 4.8 ± 2.2
Mean age at disease onset 21.6 ± 10.6 2.4 ± 2
Mean number of febrile episodes per year 8.3 ± 5.2(16/36 adult patients available) 13.3 ± 9.2
Presence of 3 cardinal signs (aphthous
stomatitis, cervical lymphadenitis, and
pharyngitis)
17/36 74/268
Combination of 2 among 3 cardinal signs 19/36 124/268
Combination of recurrent fever + only 1
cardinal sign — 70/268
Response to corticosteroids Complete response in 28, partial responsein 4, and ineffective response in 1
Complete response in 226
and
partial response in 2
Response to tonsillectomy
Complete in 1, partial in 2, and ineffective
in 13 (tonsillectomies performed during
infancy included)
Effective in 60 and
ineffective in 2
Response to anakinra 1/36 available: complete response Not administered
Response to thalidomide 1/36 available: complete response Not administered
50% of patients) [11, 14, 15]. The clinical picture may be
enriched by the presence of headache, abdominal pain,
nausea, vomiting, chills, malaise, myalgia, and arthralgia.
Some of these “minor” symptoms, such as abdominal pain,
may indeed become prominent in the clinical picture of
some patients [32]. The episodes recur very regularly with
stereotyped clinical characteristics in themajority of patients,
giving the impression that there is a “clockwork” mechanism
in the episodes. Even though clockwork periodicity is not
exclusive for PFAPA syndrome and may not be present in
a minority of children, its presence combined with com-
plete wellness between febrile episodes and normal growth
and development are nodal points for diagnostic purposes
[11]. Nonspecific symptoms such as malaise, irritability, and
fatigue may be evident during days before PFAPA flares in
up to a third of patients, and parents learn to interpret those
clinical signs as prodromes of the PFAPA febrile attack, help-
ing them in differentiating fever from other febrile episodes
secondary to infections [15, 32].The clinical characteristics of
adult patients are similar to those described in children, with
the exception that arthralgia and myalgia seem to be more
frequent in adult patients than in children, while aphthae and
chills appear to be less common [12]. Table 1 compares the
clinical characteristics of all adult PFAPA patients reported
in the literature with PFAPA patients followed up at our
centre in the last 15 years. The 3 cardinal signs (aphthosis,
pharyngitis, and cervical adenitis) were concurrently present
during attacks in 47%of adult patients versus 27%of children;
at least 2 cardinal signs were present in 52% of adult patients
versus 46% of children; the mean number of episodes/year
was 8.3 ± 5.2 in adult patients and 13.3 ± 9.2 in our PFAPA
population.
The combination of PFAPA syndrome with autoimmune
manifestations has been recently described on an individual
basis. Cazzato et al. identified an adult-onset PFAPA syn-
drome associated with endocapillary proliferative glomeru-
lonephritis, while Corte et al. reported a case of an 18-month-
old girl with PFAPA syndrome associated with type 2 autoim-
mune hepatitis, both responsive to corticosteroid therapy
[33, 34]. Recently a case of an 11-year-old boy diagnosed with
PFAPA syndrome who developed recurrent acute aseptic
encephalitis was described by Frye [35]. Finally Iba et al.
described a 7-year-old boy who was diagnosed with PFAPA
syndrome at the age of 3, who developed acute parapsoriasis
(pityriasis lichenoides and varioliformis acuta, also known
as PLEVA) when he was 5 years old [36]. These associa-
tions may be just occasional and, to date, we do not have
enough clinical or pathogenetic data to establish whether the
immune dysregulation in PFAPA patients may predispose
them to autoimmunity. Nonetheless, the concurrence of
clinical manifestations typical of both AIDs and autoimmune
disorders is evocative of the recently developed concept of
an immunological continuum, in which diseases lie on a
spectrum from autoimmune to autoinflammatory, and the
prevalence of an autoimmune versus an autoinflammatory
response in the single patient determines the clinical picture
[37, 38].
5. Laboratory Findings
No diagnostic tests for PFAPA syndrome are available
today. During PFAPA flares patients usually display mod-
erate leukocytosis with prominence of neutrophils, while
an increase in the number of monocytes, a decrease of
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eosinophilic rate, and thrombocytosis during the afebrile
period have been reported, even though these latter findings
need further confirmation and may simply be secondary
to the acute-phase response [16]. Erythrocyte sedimentation
rate and C-reactive protein are constantly raised during
febrile attacks [39, 40]. The recent finding that procalci-
tonin concentrations do not increase in correlation with
the increase of other acute-phase reactants during attacks
identifies this protein as a possible useful marker for dif-
ferentiating PFAPA syndrome from infections [41]. Serum
immunoglobulin levels are normal or close to normal, while
IgD can be normal or slightly elevated [42]. During episodes
all the cultures are negative [43]. In a recent studyYamazaki et
al. examined the utility of CD64, a member of the Fc𝛾 recep-
tors, in diagnosing patients with PFAPA syndrome. In these
patients, CD64 expression on neutrophils and monocytes
during the attack-free period was similar to that of controls,
while it was dramatically increased on both cell types during
flares [44]. Further data confirming this finding are needed
before considering CD64 expression as a diagnostic marker
for PFAPA syndrome.
6. Diagnostic Criteria and
Differential Diagnosis
As already pointed out, PFAPA syndrome is a clinical diagno-
sis. Thomas diagnostic criteria for PFAPA syndrome may be
applied to help the clinician in corroborating this diagnosis
as follows:
(1) Regularly recurring fevers with an early age of onset
(<5 years of age).
(2) Constitutional symptoms in the absence of upper
respiratory infection with at least 1 of the following
clinical signs:
(a) Aphthous stomatitis.
(b) Pharyngitis.
(c) Cervical lymphadenitis.
(3) Exclusion of cyclic neutropenia.
(4) Completely asymptomatic interval between episodes.
(5) Normal growth and development.
Noteworthily, although one of the criteria is the age at onset
of less than 5 years, it is now well-established that PFAPA
children may be older than 5 at disease onset, and PFAPA
syndrome may have its onset in adulthood, meaning that
the age criterion should not be considered mandatory for
diagnosis.
Based on the current criteria, diagnosis of PFAPA syn-
drome is made on the basis of clinical history, physical
findings, and exclusion of other causes of recurrent fevers.
For this purpose different diseases have to be excluded,
and differential diagnosis may vary on different ages. The
first diseases to exclude are infections and, in particular,
viral or bacterial pharyngitis. This is usually an easy task to
accomplish: the absence of accompanying symptoms related
to upper respiratory tract infections is usually enough in the
clinical setting to exclude viral infection, while a pharyngeal
swab is the gold standard to exclude bacterial pharyngitis.
Indeed, to differentiate infections is particularly relevant
in younger children, who have the highest incidence of
upper respiratory tract infections, but still it is crucial in
older patients as well as in adults. The occurrence of typical
attacks without a seasonal pattern is another characteristic
peculiar to PFAPA syndrome, helpful in ruling out recurrent
infections. The second diagnostic step is to exclude cyclic
neutropenia (CN), since this is the only clinical entity other
than PFAPA characterized by a regular interval between fever
attacks [11]. In CN fever usually occurs regularly every 18–
24 days and is accompanied by a decrease in the neutrophil
count with a nadir of less than 500 cells/mm3. Patients
with CN may present with pharyngitis and oral aphthosis,
but differential diagnosis may be eased by the presence of
recurrent respiratory infections and genital ulcers, which are
typical of this disease and not of PFAPA syndrome. Finally,
fever attacks due to CN do not respond to corticosteroid
administration. In case CN is hypothesized serial blood cell
count should be obtained once a week for 4–6 weeks, to
identify the neutrophil drop and, in case of high suspicion, the
genetic test looking for ELANE gene mutations is available to
confirm the diagnosis [45].
Nowadays, the main challenge for clinicians is differ-
entiating PFAPA syndrome from HPF. The current PFAPA
diagnostic criteria demonstrated indeed having very low
specificity to this regard. Gattorno et al. showed that a
relevant number of children with monogenic periodic fevers
also met the diagnostic criteria for PFAPA syndrome and
that some of the features considered characteristic of PFAPA
syndrome, as clockwork recurrence of febrile episodes, oral
aphthosis, and cervical adenitis, may be observed in different
HPF as well, particularly at their onset [46]. Moreover, it is
now well-established that HPF patients may have their onset
in adulthood, and this belated onset is probably secondary
to heterozygosity or hypomorphic mutations. In these cases
patients may have a milder clinical picture, lacking the most
typical clinical characteristics of HPF and further making
the differential diagnosis between PFAPA syndrome andHPF
difficult [47, 48].
The most frequent disease among HPF is familial Med-
iterranean fever (FMF), caused by mutations in the MEFV
gene, encoding a protein named pyrin, which is mainly
expressed in the inflammatory cells [1, 49]. Its incidence is
particularly high in populations living in the Mediterranean
basin (as Armenians, Sephardic Jews, Turks, and Arabs) [50].
Its main clinical features are represented by short and recur-
rent self-limiting episodes of fever, lasting less than 72 hours,
associated with serositis, arthralgia and/or arthritis, and
erysipelas-like erythema [51, 52]. In addition, fever attacks are
typically prevented by long-term colchicine administration
[53]. More than 60% of patients show symptoms during
childhood, usually before age of 10, but delayed onset has
frequently been reported: 98% of patients show their first
symptoms within the third decade. Adult-onset FMF seems
to be related to heterozygosity and low-penetrancemutations:
because of this genetic condition, adults often experience
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milder phenotype, whose clinical features tend to be similar
to those found in younger patients, except for a lower
rate of arthritis and erysipelas-like rash [54]. A diagnostic
confirmationmight be obtained byMEFV genotype analysis.
Mevalonate kinase deficiency syndrome (MKD), also
known as hypergammaglobulinemia-D syndrome, is caused
by homozygosity or compound heterozygosity in the meval-
onate kinase (MVK) gene, encoding mevalonate kinase, the
first enzyme in the cholesterol biosynthesis pathway [1, 55,
56]. It manifests within the first year of life in 75% of cases and
in 100%of caseswithin the first 5 years: it usually accompanies
the whole patient’s life, but flares tend to reduce in intensity
and become less frequent over time [57]. From a clinical
point of view attacks are characterized by high fever lasting
4–7 days and generally recurring every 3-4 weeks, often
associated with chills, arthralgia, lymph node enlargement,
vomiting, diarrhea, abdominal pain, splenomegaly, and oral
aphthae [58]. Cutaneous involvement is very frequent and
consists of various types of rashes [59].
Tumor necrosis factor (TNF) receptor-associated peri-
odic syndrome (TRAPS) is related tomutations in the soluble
TNF receptor super family 1A (TNFRSF1A) gene and is the
most common autosomal dominant autoinflammatory dis-
ease [60–62]. TRAPS starts with fever attacks lasting even 3
weeks and recurring at variable intervals. In addition to fever,
common clinical features that can be detected are periorbital
edema, conjunctivitis, migratory erythematous plaques with
underlying myalgia, and arthritides or arthralgias [63–65].
Also serosal membrane inflammation can occur, revealing
itself through abdominal or thoracic pain and full-blown
pericarditis [66]. TRAPS is the most variable entity among
AIDs in terms of age of disease onset, frequency, duration,
and severity of inflammatory flares, and this heterogeneity
is probably linked to the wide spectrum of TNFRSF1A
mutations. Average patients’ age at onset is around 3 years, but
adult-onset, frequently related to low-penetrance mutations,
has been reported up to the sixth decade. In addition,
adult patients with TRAPS may display atypical symptoms,
such as idiopathic recurrent acute pericarditis or myocarditis
[67–69] and sacroiliitis as unique clinical manifestations
[70, 71].
The family of cryopyrin-associated periodic syndrome
(CAPS) is linked with mutations in the NLRP3 gene, encod-
ing a structurally crucial inflammasome protein, named
cryopyrin, which directly controls the release of bioactive IL-
1𝛽 [1, 72]. The CAPS family includes three different clinical
expressions of mutations involving the same gene, all of them
starting in early childhood, with overlapping symptoms:
familial cold-associated syndrome (FCAS), Muckle-Wells
syndrome (MWS), and chronic infantile neurological cuta-
neous articular syndrome (CINCA syndrome), respectively,
mentioned from the least to the most severe [73, 74]. In
particular, FCAS is characterized by fever episodes, skin
rashes, and arthralgias, often triggered by exposure to cold
temperatures [75], while MWS is characterized by a similar
group of symptoms associated with migrating urticaria-like
lesions, ocular abnormalities, progressive sensorineural deaf-
ness, and risk of amyloidosis [76]. Skin rash in combination
with arthropathy, usually involving the knees, and chronic
meningeal involvement strikingly characterize CINCA syn-
drome [77]. Table 2 summarizes the main characteristics of
the monogenic AIDs herein described.
How can we distinguish PFAPA syndrome from mono-
genic AIDs? Given the fact that PFAPA syndrome in children
is far more common than HPF, this differential diagnosis is
the first step in the approach to a child with periodic fevers
of rheumatologic interest, and it is of outstanding priority,
since it may avoid unnecessary time- and money-consuming
genetic tests. In the majority of cases a careful clinical
examination conducted by a pediatricianwith expertise in the
field of AIDs is sufficient to rule out HPF and confirm PFAPA
diagnosis. In this context, the presence of cutaneous eruption,
severe gastrointestinal symptoms, arthralgia, and thoracic
pain during febrile episodes are the clinical characteristics
more typical of HPF compared to PFAPA syndrome, while
exudative instead of erythematous pharyngitis ismore typical
of PFAPA patients [46]. Nonetheless, as above mentioned,
younger childrenwithHPFmay have a clinical picture strictly
overlapping that of PFAPA syndrome. For this reason some
authors formulated a diagnostic score, named “Gaslini score,”
which may help in identifying those patients at higher risk
of carrying a mutation in the genes involved in HPF. Age at
onset, positive family history, thoracic and abdominal pain,
diarrhea, and oral aphthosiswere the variables included in the
final model. According to the diagnostic score, a probability
of >15% identified patients at high risk of carrying mutations
in one of the HPF genes. This tool may be of use in the
clinician’s hand for differentiating PFAPA syndrome from
monogenic hereditary causes of recurring fever [78]. When
clinicians tried to apply the pediatric score to the adult popu-
lation, most subjects carrying mutations can be identified as
low-risk patients, thus not in need for any genetic testing.This
was probably related to the fact that since the score had been
validated for children, advanced age of disease onset played
an extremely protective role, together with a phenotype
characterized by oligosymptomatic/atypical manifestations
due to low-penetrance mutations. Recently, we developed
a diagnostic score validated for adult population, with the
aim of identifying patients at high risk of carrying mutations
in MEFV and TNFRSF1A genes. MKD and CAPS were not
included, because of their early onset in childhood. Early age
at disease onset, positive family history for recurrent fever
episodes, thoracic pain, abdominal pain, and skin involve-
ment were the variables significantly associated with positive
genetic test result and were used to construct the score [79].
In 2011 Pontillo et al. tried to find out a serological marker
that could help discriminate monogenic AIDs from PFAPA
syndrome: previous studies had described the human gly-
colytic enzyme 𝛼-enolase as a potential substrate of caspase-1,
whose role in the activation of IL-1𝛽 through the inflamma-
some is nowadays well defined. Pontillo’s hypothesis was that
a high amount of anti-𝛼-enolase antibodies (AAE abs) could
be found out during processes involving caspase-1 activation.
The evaluation of AAE abs showed a difference between
PFAPA patients, almost negative for AAE abs, and those with
HPFwhich resulted positive for AAE abs [80]. Unfortunately,
to our knowledge, these results have not been replicated in
larger case series.
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Table 2: List of the genetic and clinical features of the main hereditary autoinflammatory disorders.
Disease Genelocus Protein Inheritance Clinical features
FMF MEFV16p13.3 Pyrin AR
Fever, serositis, arthralgias or arthritides, erysipelas-like
eruption on the legs, responsiveness to colchicine
prophylaxis, and amyloidosis in untreated or
noncompliant patients
TRAPS TNFRSF1A12p13
p55 tumor necrosis
factor receptor
type-1
AD
Fever, severe migrating muscle and joint involvement,
conjunctivitis, periorbital edema, arthralgias or
arthritis, sacroiliitis, serosal involvement, steroid
responsiveness of febrile attacks, and risk of amyloidosis
MKD MVK12q24 Mevalonate kinase AR
Fever, widespread polymorphous rash, arthralgias,
abdominal pain, diarrhea, lymph node enlargement,
and oral aphthosis
CAPS
FCAS
NLRP3
1q44 Cryopyrin AD
Fever, cold-induced urticaria-like rash, conjunctivitis,
arthralgias, and fatigue
MWS Fever, urticaria-like rash, conjunctivitis, arthralgias,neurosensory deafness, and risk of amyloidosis
CINCAs
Fever, urticaria-like rash, uveitis, papilledema,
deforming arthritis involving large joints, neurosensory
deafness, aseptic chronic meningopathy and
hydrocephalus, and risk of amyloidosis
AD: autosomal dominant, AR: autosomal recessive, CAPS: cryopyrin-associated periodic syndromes, CINCAs: chronic inflammatory neurological cutaneous
articular syndrome, FCAS: familial cold autoinflammatory syndrome, FMF: familial Mediterranean fever, MKD: mevalonate kinase deficiency syndrome,
MWS: Muckle-Wells syndrome, and TRAPS: tumor necrosis factor receptor-associated periodic syndrome.
Among polygenic AIDs, PFAPA syndrome and Behc¸et
disease (BD) can overlap, sharing some clinical manifesta-
tions, and this could be particularly true in the pediatric age,
when Behc¸et patients may be oligosymptomatic. We have
recently hypothesized that patients diagnosed with BD dur-
ing adulthood could have manifested symptoms compatible
with PFAPA syndrome during childhood: therefore, we con-
ducted phone interviews with 80 patients with BD applying
Marshall criteria and finding out that a variable percentage
of patients fulfilled the diagnosis of PFAPA syndrome in
childhood.This could suggest either that a common immune
imbalance might underlie both diseases or that PFAPA
syndrome may predispose to the development of BD [81, 82].
Of note, these are very preliminary and retrospective data
that need to be confirmed on larger numbers; nonetheless
they indicate that BD should be ruled out in a patient
with PFAPA-like phenotype, particularly in the pediatric age
[83].
It is quite intriguing that while PFAPA syndrome is the
first disease to be ruled out in children with a periodic fever
syndrome, given its frequency, PFAPA diagnosis in adult
patients is usually considered only after HPF have been ruled
out. This approach is certainly due to the fact that, since few
years ago, PFAPA syndromewas thought to be exclusive of the
pediatric age. Although it is the authors’ opinion that the final
diagnosis of adult PFAPA syndrome should be undertaken
after the exclusion ofHPF, this approachwill probably change
over time, if more adult PFAPA patients will be reported,
clearing out that probably this condition is more common
than HPF in adults as well.
7. Treatment
Treatment of PFAPA syndrome is still a matter of debate and
two general considerations have to be taken. First, since the
etiology of the disease is unknown, treatment is essentially
symptomatic; second, given that PFAPA is a self-limited
disease and no long-term sequelae have been described
so far, cost-effectiveness of treatment strategies should be
very carefully evaluated. Corticosteroids are successfully used
during febrile episodes. One or two doses of prednisone (1-
2mg/kg) or betamethasone (0.1–0.2mg/kg) can dramatically
abrupt fever attacks in a few hours. Other accompanying
symptoms, however, can take longer to resolve [11, 14] and,
obviously, steroid administration does not prevent further
attacks [31, 32, 84]. Corticosteroids are effective in almost
every child with PFAPA syndrome and, at this dose and
with this frequency of administration, do not have any of
the well-known effects of chronic steroid therapy. Physicians
should be very reassuring on this aspect, since parents of
PFAPA patients are often reluctant to give steroids to their
children. Steroids seem to be less effective in adult patients:
as shown in Table 1, prednisone at the dose of 50–60mg/day
was administered in 33/36 patients, with a complete response
in 28, partial response in 4, and ineffectiveness in 1. Whether
this discrepancy is secondary to intrinsic biological difference
between children- and adult-onset PFAPA syndrome or it
is just a matter of finding the right steroid dose in adults
needs further investigation. The only “side effect” related to
corticosteroid therapy is the free-interval shortening, which
can happen in up to half of children, depending on the study
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analyzed. Nine out of the 33 adults treated experienced a free-
interval shortening after steroid administration [12, 13].There
is no clear evidence whether different steroid preparations
have different efficacy or safety profile in PFAPA patients.
Prophylactic treatments have also been experimented
both with colchicine and cimetidine, though with vari-
able results. Tasher et al. published their experience on 7
patients with PFAPA syndrome, in whom a reduction in
the number of episodes was observed with the introduction
of colchicine [84]. Of 5 patients from a multicenter cohort
treated with colchicine, 2 had a complete response and 3
patients responded partially [85]. Partial efficacy of cimeti-
dine was documented in a minority of patients [14, 86]. The
overall evidence on the efficacy of colchicine or cimetidine
is very poor, and their use in clinical practice has been
hampered by the need of a continuous administration so that
these drugs are not routinely used. Lately, the association
between vitamin D and PFAPA syndrome in children has
been investigated in two independent studies [86, 87]. In
both studies vitamin D levels were lower in PFAPA children
compared to controls and, in the study by Stagi et al., vitamin
D supplementation in PFAPA patients induced a significant
reduction in the number of febrile episodes and a shortening
of mean duration of episodes in some patients. Although
these data are still to be considered as preliminary, they
focus the attention on the well-known effect of vitamin D on
immune homeostasis.
The role of tonsillectomy in PFAPA syndrome is contro-
versial. In 1989 an initial study reported that tonsillectomy
resolved PFAPA symptoms in 4 children [88]. Afterwards,
other studies addressed this issue in larger cohorts of patients
[17, 89–93], reporting a wide variability in success rates.
Renko et al. randomized 14 PFAPA patients to tonsillectomy
and 12 PFAPA patients to observation without surgery.
PFAPA syndrome resolved immediately in all 14 patients ran-
domized to tonsillectomy; however, the syndrome resolved
spontaneously within 6 months in 6/12 patients who did not
receive tonsillectomy [94]. Garavello et al. randomized 39
patients, of whom 19 underwent surgery and 20 were treated
with medical therapy. Immediate and complete resolution
after surgery was observed in 12/19 cases (63%) [95]. The 18-
month follow-up allowed to document the complete reso-
lution of symptoms in all patients who underwent surgery,
within 1 year from adenotonsillectomy. In contrast to the
findings of Renko et al., spontaneous resolution in the control
group was rare, as just 1 patient achieved remission.
A prospective study by Licameli et al. evaluated the
long-term efficacy of adenotonsillectomy in 102 patients: 99
experienced complete resolution immediately after surgery.
Of the remaining 3 patients, 1 continued having cyclic fevers
that were similar in duration and frequency to the presurgery
state.The second child, given the lack of response to tonsillec-
tomy, was further investigated and subsequently diagnosed
with MKD. The third patient kept having unchanged flares
immediately after surgery, but he had complete resolution of
the inflammatory episodes within 6 months after tonsillec-
tomy [96].
These differences, in terms of tonsillectomy efficacy, are
probably determined by the extreme heterogeneity of the
studied populations, in terms of diagnostic criteria adopted,
type of intervention (i.e., tonsillectomy versus adenotonsil-
lectomy), and length of follow-up before and after surgery.
It is the authors’ opinion that tonsillectomy remains a
highly efficacious treatment for PFAPA children but since
PFAPA syndrome is a self-limiting disease, surgery should
be reserved to patients in whom medical treatment with
corticosteroids is not a good option (e.g., children with very
short free interval between episodes or children with long-
lasting disease with parents/child discomfort). Following this
approachwe sent 62/268 PFAPA to tonsillectomy in the last 15
years: 60/62 patients had complete resolution of the episodes.
Given the fact that PFAPA syndrome in adults seems
not to be a self-limited disease, tonsillectomy would be a
good option. Unfortunately the available data seem to suggest
that tonsillectomy is not effective in adults. Data from the
most recent literature (see Table 1) show that tonsillectomy
was performed in 16/36 patients diagnosed with PFAPA
syndrome in adulthood: the response to surgery was prompt
and complete in 1 patient, partial in 2 patients, and ineffective
in 13 patients. Of 16 patients who underwent surgery, 4 had
tonsillectomy performed during infancy because of recurrent
febrile pharyngitis. In 3/4 patients, tonsillectomy achieved a
disease-free period of several years before the recurrence of
fever episodes, but it did not prevent further development of
PFAPA syndrome in adulthood. These observations are very
interesting and lead us to speculate that probably tonsillec-
tomy is efficacious in inducing a temporary remission but
that the effect is transient and that reappearance of the disease
years later can occur as a consequence of the compensatory
hypertrophy involving other lymphatic stations [97]. Further
long-term studies on children who underwent tonsillectomy
are needed to explore this point.
As data extracted from gene expression studies pro-
vided evidence of high level of some inflammasome-related
cytokines during PFAPA flares, some authors hypothesized
that patients can get benefit from IL-1 inhibitors like anakinra.
A small series of 5 children with PFAPA syndrome was
treated with a single dose of anakinra on the second day
of fever, with a dramatic response in both clinical and
laboratory parameters [21]. We recently described a case
of a 27-year-old man who was resistant to conventional
therapy (corticosteroids, colchicine, and tonsillectomy) and
was treated with anakinra, with a complete resolution of
fever attacks [98]. Although these data are very intriguing,
suggesting the central role of IL-1 in PFAPA syndrome, the
cost-effectiveness of IL-1 blockers restricts this treatment to
very selected cases [99].
8. Outcome
PFAPA syndrome is considered a self-limited disease that
generally resolves spontaneously before adolescence at least
in children [14, 90, 91]. A longer follow-up reported in
the literature was made by Wurster et al., who followed a
cohort of 59 patients for a period ranging between 12 and
21 years. Spontaneous resolution of PFAPA syndrome was
described in 50 patients, while only 9 maintained typical
cardinal PFAPA symptoms, though fever was less frequent
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and faded in severity and duration [90]. Corticosteroids and
adenotonsillectomy were effective in modifying the course
of the disease. During the follow-up period, no long-term
sequelae or other comorbidities did appear. Other studies,
with a shorter follow-up, reported a spontaneous resolution
in only 20–32% of patients.
No long-term outcome data are available for adult
patients diagnosed with PFAPA syndrome: Colotto et al.
reported a youngwomandiagnosedwith PFAPA syndrome at
the age of 21, whose flares finally resolved after administration
of prednisone and for whom no more attacks were observed
after a 5-year follow-up [97].
9. Conclusive Remarks
PFAPA syndrome is a cause of recurrent fevers of autoinflam-
matory origin. Once thought to be exclusive of the pediatric
age, it is indeed one of the commonest causes of periodic
fevers and it is nowadays clear that the disease may have
its onset in adulthood as well. Clinical features of PFAPA
adults are overlapping with those of PFAPA children. The
main difference is that, so far, it is not known whether adults
with PFAPA syndrome may spontaneously undergo clinical
remission, and tonsillectomy does not seem to be a valid
option in these patients. Anyway, the new description of
PFAPA syndrome in adults should increase awareness among
clinicians, and from now on this diagnosis should always
be considered in any adult with a long-lasting history of
recurrent and unexplained episodes of fever.
All physicians should familiarize themselves with PFAPA
syndrome and pediatric rheumatologists add it in the dif-
ferential diagnosis of AIDs and HPF, in particular. Early
recognition of the clinical characteristics will spare time- and
money-consuming investigations in these patients. Further
studies are needed to better investigate outcome and thera-
peutic options in the specific category of adults with PFAPA
syndrome.
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